IMPAIRMENT OF CARBAMAZEPINE-10, 11-EPOXIDE ELIMINATION BY VALNOCTAMIDE, A VALPROMIDE ISOMER, IN HEALTHY-SUBJECTS

被引:5
作者
PISANI, F
FAZIO, A
ARTESI, C
OTERI, G
SPINA, E
TOMSON, T
PERUCCA, E
机构
[1] UNIV MESSINA,INST NEUROL & NEUROSURG SCI,I-98100 MESSINA,ITALY
[2] UNIV PAVIA,CLIN PHARMACOL UNIT,I-27100 PAVIA,ITALY
[3] KAROLINSKA INST,DEPT CLIN PHARMACOL,S-14186 HUDDINGE,SWEDEN
[4] UNIV MESSINA,INST PHARMACOL,I-98100 MESSINA,ITALY
关键词
VALNOCTAMIDE; CARBAMAZEPINE; CARBAMAZEPINE-10,11-EPOXIDE; DRUG INTERACTION;
D O I
10.1111/j.1365-2125.1992.tb04114.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effect of the valpromide isomer valnoctamide (VCD, 200 mg three times daily for 8 days), an over-the-counter tranquillizer, on the elimination kinetics of a single oral dose of carbamazepine-10, 11-epoxide (CBZ-E, 100 mg) was investigated in healthy subjects. During VCD treatment, the half-life of CBZ-E was prolonged significantly compared with control (19.7 +/- 6.7 h vs 6.9 +/- 2.0 h, means +/- s.d., P < 0.01), and its oral clearance decreased four-fold (from 109.6 +/- 30.7 to 28.8 +/- 11.1 ml h-1 kg-1, P < 0.01). These findings indicate that VCM, like valpromide, strongly inhibits epoxide hydrolase in vivo.
引用
收藏
页码:85 / 87
页数:3
相关论文
共 14 条
[1]   CLINICAL PHARMACOKINETICS AND PHARMACOLOGICAL EFFECTS OF CARBAMAZEPINE AND CARBAMAZEPINE-10,11-EPOXIDE - AN UPDATE [J].
BERTILSSON, L ;
TOMSON, T .
CLINICAL PHARMACOKINETICS, 1986, 11 (03) :177-198
[2]   PHARMACOKINETICS OF VALPROMIDE AFTER ORAL-ADMINISTRATION OF A SOLUTION AND A TABLET TO HEALTHY-VOLUNTEERS [J].
BIALER, M ;
RUBINSTEIN, A ;
RAZ, I ;
ABRAMSKY, O .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 27 (04) :501-503
[3]   PHARMACOKINETICS OF A VALPROMIDE ISOMER, VALNOCTAMIDE, IN HEALTHY-SUBJECTS [J].
BIALER, M ;
HAJYEHIA, A ;
BARZAGHI, N ;
PISANI, F ;
PERUCCA, E .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 38 (03) :289-291
[4]  
CHAMBON JP, 1980, NEUROSCI LETT S, V5, pS327
[5]   STRUCTURE-PHARMACOKINETIC RELATIONSHIPS IN A SERIES OF SHORT FATTY-ACID AMIDES THAT POSSESS ANTICONVULSANT ACTIVITY [J].
HAJYEHIA, A ;
BIALER, M .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1990, 79 (08) :719-724
[6]   INHIBITION OF HUMAN-LIVER MICROSOMAL EPOXIDE HYDROLASE BY VALPROATE AND VALPROMIDE - INVITRO INVIVO CORRELATION [J].
KERR, BM ;
RETTIE, AE ;
EDDY, AC ;
LOISEAU, P ;
GUYOT, M ;
WILENSKY, AJ ;
LEVY, RH .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 46 (01) :82-93
[7]   SIMULTANEOUS HPLC DETERMINATION OF OXCARBAZEPINE, CARBAMAZEPINE AND THEIR METABOLITES IN SERUM [J].
KUMPS, A .
JOURNAL OF LIQUID CHROMATOGRAPHY, 1984, 7 (06) :1235-1241
[8]  
MEIJER JWA, 1984, LANCET, V1, P802
[9]  
PACIFICI GM, 1985, LANCET, V2, P397
[10]   INTERACTION OF CARBAMAZEPINE-10,11-EPOXIDE, AN ACTIVE METABOLITE OF CARBAMAZEPINE, WITH VALPROATE - A PHARMACOKINETIC STUDY [J].
PISANI, F ;
CAPUTO, M ;
FAZIO, A ;
OTERI, G ;
RUSSO, M ;
SPINA, E ;
PERUCCA, E ;
BERTILSSON, L .
EPILEPSIA, 1990, 31 (03) :339-342